Paper35975201
Advance trends in targeting homology-directed repair for accurate gene editing: An inclusive review of small molecules and modified CRISPR-Cas9 systems.
Shams F and 6 others. Bioimpacts, 2022. Cited by 37 papers, by iCite.
Cite this record
ConductScience Library. Advance trends in targeting homology-directed repair for accurate gene editing: An inclusive review of small molecules and modified CRISPR-Cas9 systems. Papers, record 35975201. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35975201
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Advance trends in targeting homology-directed repair for accurate gene editing: An inclusive review of small molecules and modified CRISPR-Cas9 systems.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References144
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25580527 | Mechanisms of ATM Activation. | Annu Rev Biochem | 2015 | https://conductscience.org/library/papers/25580527 | PubMed |
| 2 | 27851729 | In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. | Nature | 2016 | https://conductscience.org/library/papers/27851729 | PubMed |
| 3 | 33339441 | Various Aspects of a Gene Editing System-CRISPR-Cas9. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/33339441 | PubMed |
| 4 | 19773431 | Identification of a small molecule inhibitor of the human DNA repair enzyme polynucleotide kinase/phosphatase. | Cancer Res | 2009 | https://conductscience.org/library/papers/19773431 | PubMed |
| 5 | 30771412 | Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9. | J Control Release | 2019 | https://conductscience.org/library/papers/30771412 | PubMed |
| 6 | 31551253 | Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814. | Mol Cancer Res | 2019 | https://conductscience.org/library/papers/31551253 | PubMed |
| 7 | 28462777 | Synthetically modified guide RNA and donor DNA are a versatile platform for CRISPR-Cas9 engineering. | Elife | 2017 | https://conductscience.org/library/papers/28462777 | PubMed |
| 8 | 32220971 | Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models. | Mol Cancer Ther | 2020 | https://conductscience.org/library/papers/32220971 | PubMed |
| 9 | 20597553 | Proteomic analysis of annexin A2 phosphorylation induced by microtubule interfering agents and kinesin spindle protein inhibitors. | J Proteome Res | 2010 | https://conductscience.org/library/papers/20597553 | PubMed |
| 10 | 29751014 | A Versatile Tool for the Quantification of CRISPR/Cas9-Induced Genome Editing Events in Human Hematopoietic Cell Lines and Hematopoietic Stem/Progenitor Cells. | J Mol Biol | 2019 | https://conductscience.org/library/papers/29751014 | PubMed |
| 11 | 29500128 | Therapeutic Genome Editing With CRISPR/Cas9 in a Humanized Mouse Model Ameliorates α1-antitrypsin Deficiency Phenotype. | EBioMedicine | 2018 | https://conductscience.org/library/papers/29500128 | PubMed |
| 12 | 19214211 | Attenuation of zinc finger nuclease toxicity by small-molecule regulation of protein levels. | PLoS Genet | 2009 | https://conductscience.org/library/papers/19214211 | PubMed |
| 13 | 26857072 | Chemical and Biophysical Modulation of Cas9 for Tunable Genome Engineering. | ACS Chem Biol | 2016 | https://conductscience.org/library/papers/26857072 | PubMed |
| 14 | 29610531 | Small molecules promote CRISPR-Cpf1-mediated genome editing in human pluripotent stem cells. | Nat Commun | 2018 | https://conductscience.org/library/papers/29610531 | PubMed |
| 15 | 29889212 | Efficient generation of targeted large insertions by microinjection into two-cell-stage mouse embryos. | Nat Biotechnol | 2018 | https://conductscience.org/library/papers/29889212 | PubMed |
| 16 | 30607331 | The Impact of CRISPR-Cas System on Antiviral Therapy. | Adv Pharm Bull | 2018 | https://conductscience.org/library/papers/30607331 | PubMed |
| 17 | 32899704 | Methods Favoring Homology-Directed Repair Choice in Response to CRISPR/Cas9 Induced-Double Strand Breaks. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32899704 | PubMed |
| 18 | 18275380 | Mechanism of eukaryotic homologous recombination. | Annu Rev Biochem | 2008 | https://conductscience.org/library/papers/18275380 | PubMed |
| 19 | 12442171 | Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. | Nature | 2002 | https://conductscience.org/library/papers/12442171 | PubMed |
| 20 | 32036573 | TIRR: a potential front runner in HDR race-hypotheses and perspectives. | Mol Biol Rep | 2020 | https://conductscience.org/library/papers/32036573 | PubMed |
Cited by31
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 37 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42610144 | AI-driven CRISPR strategies in breast cancer: Organoid modeling, adaptive editing, and precision delivery. | Iran J Basic Med Sci | 2026 | https://conductscience.org/library/papers/42610144 | PubMed |
| 42584708 | CRISPR/Cas9-based repair of a heterozygous HNF1A mutation in patient-derived hiPSCs. | Hum Genet | 2026 | https://conductscience.org/library/papers/42584708 | PubMed |
| 42300182 | Azide-functionalized SpCas9 enables generation of site-selective and bioactive Cas9-siRNA conjugates. | Chem Commun (Camb) | 2026 | https://conductscience.org/library/papers/42300182 | PubMed |
| 41972732 | CRISPR-Cas9 Therapeutics in Early Clinical Development: Delivery and Molecular Diagnostics. | Cells | 2026 | https://conductscience.org/library/papers/41972732 | PubMed |
| 41705810 | Viral genome editing methods and applications in the CRISPR era. | J Virol | 2026 | https://conductscience.org/library/papers/41705810 | PubMed |
| 41648661 | Enhancing CRISPR Homology Directed Repair in IAL-PiD2 Insect Cells via Reagent Delivery Optimization and Cell Synchronization. | Biochem Eng J | 2026 | https://conductscience.org/library/papers/41648661 | PubMed |
| 41634544 | Strategies and considerations for the generation of ssDNA-Based HDR templates for CRISPR-based genome editing. | BMC Genomics | 2026 | https://conductscience.org/library/papers/41634544 | PubMed |
| 41181132 | Multiplex engineering and multifunction T cells for precise and effective immunotherapies. | Front Immunol | 2025 | https://conductscience.org/library/papers/41181132 | PubMed |
| 41073589 | Bio-digital feedback loop systems: a synergistic integration of predictive genomics, genome editing, and AI-driven phenomic synthesis for next-generation edible and medicinal mushroom breeding. | Antonie Van Leeuwenhoek | 2025 | https://conductscience.org/library/papers/41073589 | PubMed |
| 41004518 | Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out. | PLoS One | 2025 | https://conductscience.org/library/papers/41004518 | PubMed |
| 40756867 | A bioinformatic analysis of gene editing off-target loci altered by common polymorphisms, using 'PopOff'. | J R Soc N Z | 2025 | https://conductscience.org/library/papers/40756867 | PubMed |
| 40627177 | Applications of CRISPR-Cas9 in mitigating cellular senescence and age-related disease progression. | Clin Exp Med | 2025 | https://conductscience.org/library/papers/40627177 | PubMed |
| 40432836 | Updates on SPOP Gene Mutations in Prostate Cancer and Computational Insights From TCGA cBioPortal Database. | Scientifica (Cairo) | 2025 | https://conductscience.org/library/papers/40432836 | PubMed |
| 40362595 | CRISPR/Cas9 Ribonucleoprotein Delivery Enhanced by Lipo-Xenopeptide Carriers and Homology-Directed Repair Modulators: Insights from Reporter Cell Lines. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40362595 | PubMed |
| 40231503 | CRISPR/Cas9 Technology for Modifying Immune Checkpoint in CAR-T Cell Therapy for Hematopoietic Malignancies. | Curr Gene Ther | 2026 | https://conductscience.org/library/papers/40231503 | PubMed |
| 40083649 | Rescue of the disease-associated phenotype in CRISPR-corrected hiPSCs as a therapeutic approach for inherited retinal dystrophies. | Mol Ther Nucleic Acids | 2025 | https://conductscience.org/library/papers/40083649 | PubMed |
| 39781718 | CRISPR/Cas System: A Powerful Strategy to Improve Monogenic Human Diseases as Therapeutic Delivery; Current Applications and Challenges. | Curr Gene Ther | 2025 | https://conductscience.org/library/papers/39781718 | PubMed |
| 39456792 | Reporter Alleles in hiPSCs: Visual Cues on Development and Disease. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39456792 | PubMed |
| 38699288 | Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence. | Mol Ther Methods Clin Dev | 2024 | https://conductscience.org/library/papers/38699288 | PubMed |
| 38473704 | Current Strategies for Increasing Knock-In Efficiency in CRISPR/Cas9-Based Approaches. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38473704 | PubMed |
Genes57
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35975201
GET https://conductscience.org/api/papers/v1/35975201/references?page=2